To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

CANCER DRUG PRICES

TODAY'S HEADLINES

Sharp price increases for cancer drugs

A majority of oncology drugs—particularly older drugs—had price hikes in 2015, according to a new study. Plus, the price for one leukemia drug went up four times this year to reach $199,000 annually. Read more

Big savings expected with new generic antipsychotic

FDA tentatively approved the abbreviated new drug application (ANDA) for the generic of the blockbuster drug Seroquel XR to treat schizophrenia and manic/mixed episodes associated with bipolar disorder.
There are no other generic versions of Seroquel XR available in the US market. Read more

CONTINUING PHARMACY EDUCATION

Rheumatoid arthritis: partnering for optimal care

This month's CE activity, "Rheumatoid arthritis: partnering for optimal care," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians in how to best assist patients in the use of medications to treat rheumatoid arthritis.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

First "artificial pancreas" approved for diabetes, plus 2 more FDA actions

FDA recently approved several medications and devices across several therapy areas: diabetes, weight loss and rare, auto-inflammatory diseases, including the first device to automatically monitor blood sugar and provide appropriate basal insulin doses for patients with type 1 diabetes. Read more

October 19, 2016

Related Articles

Cancer drug prices not linked to survival rates

FDA approves cariprazine for treatment of schizophrenia

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us